• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

COVID-19对血液透析患者的影响:一项系统综述

Repercussions of COVID-19 in hemodialysis patients: a systematic review.

作者信息

Frota-Cavalcante Tahissa, Castro-Jansen Raphaella, de Souza-Maciel-Ferreira José Erivelton, Meirú-de-Lima Cristefania, Candido-Morais Huana Carolina, Pessoa-Moreira Rafaella

机构信息

. University of International Integration of Afro-Brazilian Lusophony, Brazil. Email:

出版信息

Rev Cuid. 2023 Mar 31;13(3):e2695. doi: 10.15649/cuidarte.2695. eCollection 2022 Sep-Dec.

DOI:10.15649/cuidarte.2695
PMID:40115367
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11559295/
Abstract

INTRODUTION

The immunosuppressive state of patients with CKD increases their risk of developing poor clinical outcomes if they acquire COVID-19 infection.

OBJECTIVE

To identify the scientific evidence about the repercussions of COVID-19 in hemodialysis patients.

MATERIALS AND METHODS

A systematic review was conducted in this study. The databases Cochrane Library, Web of Science, Science Direct, PubMed, and Virtual Health Library were searched to identify relevant studies. The methodological quality of the studies was assessed using the adapted Downs and Black checklist. The review adhered to the PRISMA guidelines.

RESULTS

A total of 16 articles were included after the screening process. All articles had a methodological quality higher than 66.8%. The most common repercussions of COVID-19 in hemodialysis patients were the increased mortality rate (75%), development of typical signs and symptoms of the disease such as fever, cough, dyspnea, and fatigue (68.75%), lymphopenia (68.75%), progression to severe acute respiratory syndrome (56.25%), need for mechanical ventilation (50%), and admission to intensive (50%).

CONCLUSIONS

The hemodialysis patients are more susceptible to COVID-19 infection and, when infected by SARS-CoV-2, these patients have more adverse clinical outcomes, more serious diseases, higher mortality, and worse prognosis than the general population. The repercussions of COVID-19 in hemodialysis patients reveal a need for preventive nursing care in hemodialysis clinics.

摘要

引言

慢性肾脏病患者的免疫抑制状态会增加他们感染新冠病毒后出现不良临床结局的风险。

目的

确定关于新冠病毒对血液透析患者影响的科学证据。

材料与方法

本研究进行了系统评价。检索了Cochrane图书馆、科学网、科学Direct、PubMed和虚拟健康图书馆等数据库以识别相关研究。使用改编后的唐斯和布莱克检查表评估研究的方法学质量。该评价遵循PRISMA指南。

结果

筛选过程后共纳入16篇文章。所有文章的方法学质量均高于66.8%。新冠病毒对血液透析患者最常见的影响包括死亡率增加(75%)、出现疾病的典型体征和症状如发热、咳嗽、呼吸困难和疲劳(68.75%)、淋巴细胞减少(68.75%)、进展为严重急性呼吸综合征(56.25%)、需要机械通气(50%)以及入住重症监护病房(50%)。

结论

血液透析患者更容易感染新冠病毒,并且当感染新冠病毒时,这些患者比普通人群有更多不良临床结局、更严重的疾病、更高的死亡率和更差的预后。新冠病毒对血液透析患者的影响表明血液透析诊所需要预防性护理。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b2b9/11559295/60ade81cd768/2346-3414-cuid-13-03-e2695-gf2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b2b9/11559295/d28f3faf11a5/2346-3414-cuid-13-03-e2695-gf1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b2b9/11559295/60ade81cd768/2346-3414-cuid-13-03-e2695-gf2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b2b9/11559295/d28f3faf11a5/2346-3414-cuid-13-03-e2695-gf1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b2b9/11559295/60ade81cd768/2346-3414-cuid-13-03-e2695-gf2.jpg

相似文献

1
Repercussions of COVID-19 in hemodialysis patients: a systematic review.COVID-19对血液透析患者的影响:一项系统综述
Rev Cuid. 2023 Mar 31;13(3):e2695. doi: 10.15649/cuidarte.2695. eCollection 2022 Sep-Dec.
2
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
3
Colchicine for the treatment of COVID-19.秋水仙碱治疗 COVID-19。
Cochrane Database Syst Rev. 2021 Oct 18;10(10):CD015045. doi: 10.1002/14651858.CD015045.
4
Remdesivir for the treatment of COVID-19.瑞德西韦用于治疗新型冠状病毒肺炎。
Cochrane Database Syst Rev. 2021 Aug 5;8(8):CD014962. doi: 10.1002/14651858.CD014962.
5
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.在基层医疗或医院门诊环境中,出现症状和体征来确定患者是否患有 COVID-19。
Cochrane Database Syst Rev. 2021 Feb 23;2(2):CD013665. doi: 10.1002/14651858.CD013665.pub2.
6
Risk factors for mortality in COVID-19 patients in sub-Saharan Africa: A systematic review and meta-analysis.撒哈拉以南非洲地区 COVID-19 患者死亡的风险因素:系统评价和荟萃分析。
PLoS One. 2022 Oct 17;17(10):e0276008. doi: 10.1371/journal.pone.0276008. eCollection 2022.
7
Ivermectin for preventing and treating COVID-19.伊维菌素预防和治疗 COVID-19。
Cochrane Database Syst Rev. 2022 Jun 21;6(6):CD015017. doi: 10.1002/14651858.CD015017.pub3.
8
Remdesivir for the treatment of COVID-19.瑞德西韦治疗 COVID-19。
Cochrane Database Syst Rev. 2023 Jan 25;1(1):CD014962. doi: 10.1002/14651858.CD014962.pub2.
9
Early versus late tracheostomy in critically ill COVID-19 patients.危重症 COVID-19 患者的早期与晚期气管切开术。
Cochrane Database Syst Rev. 2023 Nov 20;11(11):CD015532. doi: 10.1002/14651858.CD015532.
10
Mortality rate of COVID-19 infection in end stage kidney disease patients on maintenance hemodialysis: A systematic review and meta-analysis.维持性血液透析的终末期肾病患者中新冠病毒感染的死亡率:一项系统评价和荟萃分析。
World J Virol. 2022 Sep 25;11(5):352-361. doi: 10.5501/wjv.v11.i5.352.

本文引用的文献

1
Hypothermia related to continuous renal replacement therapy: incidence and associated factors.连续性肾脏替代治疗相关低温:发生率及相关因素。
Rev Bras Ter Intensiva. 2021 Jan-Mar;33(1):111-118. doi: 10.5935/0103-507X.20210012.
2
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.PRISMA 2020 声明:系统评价报告的更新指南。
BMJ. 2021 Mar 29;372:n71. doi: 10.1136/bmj.n71.
3
[Epidemiologic and clinical profile, 90 days survival of incident end stage renal patient in haemodialysis during SARS-CoV2 pandemic: Experience of the General Hospital of Douala].
[新冠疫情期间杜阿拉总医院终末期肾病血液透析患者的流行病学与临床特征及90天生存率:经验总结]
Nephrol Ther. 2021 Aug;17(4):226-232. doi: 10.1016/j.nephro.2020.12.002. Epub 2021 Jan 6.
4
Identifying prognostic risk factors for poor outcome following COVID-19 disease among in-centre haemodialysis patients: role of inflammation and frailty.确定中心血液透析患者 COVID-19 疾病后不良预后的预后风险因素:炎症和虚弱的作用。
J Nephrol. 2021 Apr;34(2):315-323. doi: 10.1007/s40620-020-00960-5. Epub 2021 Jan 30.
5
Mortality analysis of COVID-19 infection in chronic kidney disease, haemodialysis and renal transplant patients compared with patients without kidney disease: a nationwide analysis from Turkey.土耳其全国性分析:与无肾病患者相比,慢性肾脏病、血液透析和肾移植患者 COVID-19 感染的死亡率分析。
Nephrol Dial Transplant. 2020 Dec 4;35(12):2083-2095. doi: 10.1093/ndt/gfaa271.
6
C-Reactive protein as a prognostic indicator in hospitalized patients with COVID-19.C 反应蛋白作为 COVID-19 住院患者的预后指标。
PLoS One. 2020 Nov 20;15(11):e0242400. doi: 10.1371/journal.pone.0242400. eCollection 2020.
7
COVID-19 and the gastrointestinal tract: what do we already know?新型冠状病毒肺炎与胃肠道:我们目前了解到了什么?
Einstein (Sao Paulo). 2020 Nov 13;18:eRW5909. doi: 10.31744/einstein_journal/2020RW5909. eCollection 2020.
8
Sociodemographic features and mortality of individuals on haemodialysis treatment who test positive for SARS-CoV-2: A UK Renal Registry data analysis.血透患者 SARS-CoV-2 检测呈阳性的人口统计学特征和死亡率:英国肾脏登记数据分析。
PLoS One. 2020 Oct 23;15(10):e0241263. doi: 10.1371/journal.pone.0241263. eCollection 2020.
9
COVID-19 in patients undergoing chronic kidney replacement therapy and kidney transplant recipients in Scotland: findings and experience from the Scottish renal registry.苏格兰慢性肾脏替代治疗患者和肾移植受者中的 COVID-19:苏格兰肾脏登记处的发现和经验。
BMC Nephrol. 2020 Oct 1;21(1):419. doi: 10.1186/s12882-020-02061-8.
10
Role of Screening for COVID-19 in Hemodialysis Wards, Results of a Single Center Study.血液透析病房中新冠病毒病筛查的作用:一项单中心研究结果
Iran J Kidney Dis. 2020 Sep;14(5):389-398.